Frequent MGMT (0⁶-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience

Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-18.10.2478/v10019-010-0007-ySearch in Google Scholar

Kachanov DY, 2, Dobrenkov KV, Shamanskaya TV, 2, Abdullaev RT, 2, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.10.2478/v10019-007-0037-2Search in Google Scholar

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.10.1016/S1470-2045(09)70025-7Search in Google Scholar

Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 2007; 82: 133-9.10.1007/s11060-006-9264-4Search in Google Scholar

Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8: 180-7.Search in Google Scholar

Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nägele T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: The patient's perspective. Neurology 2006; 66: 239-42.10.1212/01.wnl.0000194221.89948.a0Search in Google Scholar

Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002; 62: 6205-10.Search in Google Scholar

McLendon RE and Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003; 98: 1745-8.10.1002/cncr.11666Search in Google Scholar

Senger D, Cairncross JG, Forsyth PAJ. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J 2003; 9: 214-21.10.1097/00130404-200305000-00009Search in Google Scholar

Scott JN, Rewcastle NB, Brasher PMA, Fulton D, MacKinnon JA, Hamilton M, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999; 46: 183-8.10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.0.CO;2-7Search in Google Scholar

Vertosick FT, Selker RG. Long-term survival after the diagnosis of malignant glioma. A series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 1992; 38: 359-63.10.1016/0090-3019(92)90022-FSearch in Google Scholar

Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM. Long-term survival in patients with supratentorial glioblastoma. J Neurooncol 1998; 36: 61-4.10.1023/A:1017926603341Search in Google Scholar

Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 1996; 27: 259-66.10.1007/BF00165483Search in Google Scholar

Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme. Anticancer Res 2005; 25: 4605-10.Search in Google Scholar

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9: 29-38.10.1016/S1470-2045(07)70384-4Search in Google Scholar

Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Rad Oncol Biol Phys 1998; 40: 51-5.10.1016/S0360-3016(97)00485-9Search in Google Scholar

Vranic A. Antigen expression on recurrent meningioma cells. Radiol Oncol 2010; 44: 107-12.10.2478/v10019-010-0028-6342368322933900Search in Google Scholar

Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 2007; 83: 91-3.10.1007/s11060-006-9292-017164975Search in Google Scholar

Hau P, Stupp R, Hegi ME. MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers 2007; 23: 97-104.10.1155/2007/159242385164117325429Search in Google Scholar

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005; 352: 997-1003.10.1056/NEJMoa04333115758010Search in Google Scholar

Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009; 27: 1257-6110.1200/JCO.2008.19.219519188676Search in Google Scholar

Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 2009; 151: 1349-58.10.1007/s00701-009-0387-119730774Search in Google Scholar

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130: 2596-606.10.1093/brain/awm20417785346Search in Google Scholar

Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, et al. O⁶-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9: 1461-8.Search in Google Scholar

Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O⁶-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004; 54: 349-57.10.1227/01.NEU.0000103422.51382.99Search in Google Scholar

Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004; 68: 275-83.10.1023/B:NEON.0000033385.37098.85Search in Google Scholar

Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest 2006; 24: 35-40.10.1080/0735790050044954616466990Search in Google Scholar

Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.10.1056/NEJM20001109343190111070098Search in Google Scholar

Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neurooncologia (GICNO). Br J Cancer 2006; 95: 1155-60.10.1038/sj.bjc.6603376236056017024124Search in Google Scholar

Hassler M, Seidl S, Fazeny-Doerner B, Preusser M, Hainfellner J, Rössler K, et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet 2006; 166: 46-55.10.1016/j.cancergencyto.2005.08.02116616111Search in Google Scholar

Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007; 83: 173-9.10.1007/s11060-006-9320-017219056Search in Google Scholar

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-4.10.1158/1078-0432.CCR-03-038415041700Search in Google Scholar

Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24: 4412-7.10.1200/JCO.2006.06.910416983109Search in Google Scholar

Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Labor Invest 2007; 87: 392-7.10.1038/labinvest.370052017260000Search in Google Scholar

Aldape KD, Jones G, Wang M, Hegi M, Janzer RC, Stupp R, et al. MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma [abstract]. J Clin Oncol 2009; 27(Suppl), 15S. No. 2051.10.1200/jco.2009.27.15_suppl.2051Search in Google Scholar

Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus 2006; 20: 1-6.Search in Google Scholar

Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, De Campos JM, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 2003; 22: 601-8.Search in Google Scholar

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010; 6: 39-51.10.1038/nrneurol.2009.19719997073Search in Google Scholar

Preusser M, Elezi L, Hainfellner JA. Poor reliability and reproducibility of PCR-based testing of O⁶-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 2008; 27: 388-90.10.5414/NPP2738819130735Search in Google Scholar

Ho DM, Hsu CY, Ting LT, Chiang H. MIB-1 and DNA Topoisomerase IIα could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol 2003; 119: 715-22.10.1309/UN4WV65UH94JEWUVSearch in Google Scholar

Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C. Glioblastoma multiforme with long-term survival. Neurol India 2005; 53: 329-32.10.4103/0028-3886.16934Search in Google Scholar

Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J Neurooncol 2009; 95: 301-5.10.1007/s11060-009-9946-919557499Search in Google Scholar

Gojkovic Horvat A, Kovac V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases. Radiol Oncol 2009; 43: 213-24.Search in Google Scholar

Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 2005; 26: 2466-74.Search in Google Scholar

Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996; 27: 65-73.10.1007/BF001460868699228Search in Google Scholar